Salt Lake City-based Huntsman Cancer Institute at the University of Utah will be the first U.S. academic medical center to manufacture a novel prostate cancer imaging drug, flotufolastat F 18.
The drug was developed by Blue Earth Diagnostics and will be manufactured through Huntsman Cancer Institute’s Center for Quantitative Cancer Imaging and Theranostics, according to a Feb. 10 news release from the institute.
Flotufolastat F 18, also known as Posluma, enables more accurate detection and staging of prostate cancer tumors by binding to cells that express a prostate-specific membrane antigen.
Posluma will be the third prostate-specific membrane antigen drug manufactured at Huntsman Cancer Institute, the release said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.